Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
TARRYTOWN, N.Y., April 07, 2024 Regeneron Pharmaceuticals, Inc. today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of.
TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial
Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration and European Medicines Agency TARRYTOWN, N.Y., April 07, 2024 Regeneron.